Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Liposomal Bupivacaine Nerve Block for Knee Replacement Pain: Added Value and Optimization

Added Value and Optimization Strategies of Liposomal Bupivacaine Targeted Nerve Block in Multimodal Analgesia for Total Knee Arthroplasty: A Prospective, Randomized, Double-Blind, Three-Arm Controlled Clinical Trial

Background Total knee arthroplasty (TKA) effectively relieves end-stage knee osteoarthritis, yet moderate-to-severe postoperative pain substantially compromises early functional exercise and rehabilitation. Liposomal bupivacaine, with a duration of action of up to 72 hours, offers a means of extending the postoperative pain-free window. However, previous studies have been limited by non-standardized background analgesia, absent head-to-head comparison of block targets, reliance on short-term resting pain scores, and inadequate blinding. Consequently, both the added value of liposomal bupivacaine nerve block on top of intravenous patient-controlled analgesia (IV-PCA) plus local infiltration analgesia (LIA), and the optimal block target, remain unresolved.

Objective To determine the analgesic added value of a single-shot liposomal bupivacaine targeted nerve block superimposed on standardized multimodal analgesia, and to compare the analgesic and functional recovery profiles of alternative block targets, thereby informing an optimized perioperative analgesic strategy.

Methods In this prospective, randomized, double-blind, three-arm controlled trial, 〔n〕 patients scheduled for unilateral TKA will be randomized to 〔arms to be confirmed: (1) background analgesia alone; (2) adductor canal block (ACB); (3) ACB combined with IPACK block〕. All patients receive standardized background analgesia comprising IV-PCA and intraoperative LIA. The primary endpoint is movement-evoked pain numeric rating scale (NRS) score at 〔24〕 h postoperatively. Secondary endpoints include resting pain scores, cumulative opioid consumption, time to first ambulation, knee range of motion, incidence of postoperative nausea and vomiting (PONV), and length of hospital stay.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

210

Phase

  • N'est pas applicable

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

65 ans à 85 ans (Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:Age 65 to 85 years at the time of surgery. Scheduled for elective unilateral total knee arthroplasty for end-stage knee osteoarthritis.

Body mass index ≥18.5 and <25 kg/m². American Society of Anesthesiologists (ASA) physical status I to III. Written informed consent obtained from the patient before any study procedure. Able to understand and use the numeric rating scale (NRS) for pain and to complete the quality-of-recovery questionnaire.

Exclusion Criteria:Refusal to participate, or withdrawal of consent at any time.

Known allergy or hypersensitivity to bupivacaine, ropivacaine, oxycodone, or other study-related medications.

Infection at or near the planned puncture sites, or systemic infection. Coagulopathy, or current anticoagulant/antiplatelet therapy that precludes deep peripheral nerve block.

Pre-existing peripheral neuropathy, motor or sensory deficit in the operated limb, or other contraindication to neuraxial/peripheral block.

Chronic opioid use (≥3 months) or a history of opioid dependence. Severe hepatic or renal impairment (e.g. eGFR <30 mL/min/1.73 m², or Child-Pugh class B/C).

Severe cardiopulmonary disease (e.g. unstable angina, NYHA class III-IV heart failure, severe COPD), or ASA physical status IV or higher.

Preoperative knee flexion contracture >15° or varus deformity >15°, or previous surgery on the index knee (including prior arthroplasty).

Cognitive impairment, psychiatric disorder, illiteracy, or language barrier that would prevent valid pain and recovery assessment.

Participation in another interventional trial within 30 days. Vulnerable populations: minors, pregnant or lactating women, prisoners, and persons unable to give voluntary informed consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Adductor Canal Block (ACB)

Liposomal bupivacaine is a multivesicular liposomal formulation of bupivacaine that provides prolonged release of the local anesthetic from the injection site. In this trial it is administered as a single injection under ultrasound guidance, at a dose of 〔133 mg/10 mL〕 for the adductor canal block and 〔133 mg/10 mL〕 for the IPACK block, with the total dose per patient not exceeding 266 mg. The preparation is used in accordance with the manufacturer's instructions and is not admixed with other local anesthetics.

A single-shot adductor canal block is performed by an anesthesiologist experienced in regional anesthesia, after induction of anesthesia and before surgical incision. With the patient supine and the operative limb abducted and externally rotated, a high-frequency linear transducer is placed on the medial mid-thigh at the level between the anterior superior iliac spine and the patella. Under real-time in-plane guidance, a 22-gauge needle is advanced from lateral to medial until the tip lies deep to the sartorius muscle, adjacent to the superficial femoral artery within the adductor canal. After negative aspiration, the study solution is injected with intermittent aspiration, and circumferential spread around the artery is confirmed by hydrodissection.

Expérimental: ACB Plus IPACK Block

Liposomal bupivacaine is a multivesicular liposomal formulation of bupivacaine that provides prolonged release of the local anesthetic from the injection site. In this trial it is administered as a single injection under ultrasound guidance, at a dose of 〔133 mg/10 mL〕 for the adductor canal block and 〔133 mg/10 mL〕 for the IPACK block, with the total dose per patient not exceeding 266 mg. The preparation is used in accordance with the manufacturer's instructions and is not admixed with other local anesthetics.

A single-shot adductor canal block is performed by an anesthesiologist experienced in regional anesthesia, after induction of anesthesia and before surgical incision. With the patient supine and the operative limb abducted and externally rotated, a high-frequency linear transducer is placed on the medial mid-thigh at the level between the anterior superior iliac spine and the patella. Under real-time in-plane guidance, a 22-gauge needle is advanced from lateral to medial until the tip lies deep to the sartorius muscle, adjacent to the superficial femoral artery within the adductor canal. After negative aspiration, the study solution is injected with intermittent aspiration, and circumferential spread around the artery is confirmed by hydrodissection.

A single-shot IPACK (interspace between the popliteal artery and the capsule of the posterior knee) block is performed with the patient supine and the knee flexed approximately 30 degrees. A high-frequency linear transducer is positioned in the popliteal crease with the popliteal artery identified in short axis, and a 22-gauge needle is advanced in-plane from medial to lateral until the tip lies in the fascial plane between the popliteal artery and the posterior capsule of the knee. After negative aspiration, the study solution is injected with real-time visualization of spread along this plane, without puncturing the popliteal vessels.

Aucune intervention: Background Analgesia Alone

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Proportion of Patients Achieving Pain-Free Rehabilitation Within 72 Hours After Surgery (Composite)
Délai: 72 hours after surgery

Composite primary endpoint, defined as the proportion of patients meeting all three of the following criteria within 72 hours after surgery: (1) adequate pain control-numeric rating scale (NRS) score ≤3 for movement-evoked pain during 45° knee flexion at 24, 48, and 72 hours postoperatively; (2) functional progress-ability to walk ≥20 m with assistance within 72 hours; and (3) opioid sparing-cumulative intravenous oxycodone consumption ≤40 mg (or morphine-equivalent dose) from 0 to 72 hours postoperatively.

72 hours after surgery

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

1 décembre 2028

Achèvement de l'étude (Estimé)

1 décembre 2028

Dates d'inscription aux études

Première soumission

10 novembre 2026

Première soumission répondant aux critères de contrôle qualité

10 novembre 2026

Première publication (Réel)

16 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner